NRG announced on January 17, 2019 that the Kansen voor West organization has awarded a subsidy of €6.8 million to develop the Petten FIELD-LAB. FIELD-LAB is an initiative of the Advancing Nuclear Medicine consortium. NucMed is proud to be one of the consortium partners.
Advancing Nuclear Medicine
The ANM consortium believes that the effective development of a new generation of nuclear therapies is optimized by using this new Field Lab in a collaborative manner. Participating organizations include the Netherlands Cancer Institute – Antoni van Leeuwenhoek, Stichting Voorbereiding Pallas, Radboudumc, Erasmus MC, Amsterdam UMC, FutureChemistry and NucMed.
NucMed firmly believes that everyone should get the best health care available, including the unique value of nuclear medicine. NucMed is actively supporting the industrialisation and commercialization of existing and new radio-isotopes and radio-chemicals, including finding better ways of production of these lifesaving products.
NucMed and the FIELD LAB
NucMed is proud member of the industry board of the FIELD LAB and will advise the consortium on how to transfer conceptual ideas to products that will be used to treat patients. The FIELD lab will play a key role throughout this transition. Especially the involvement of SMEs (“MKB”) and the bridging with big(ger) pharma companies is a focus area for NucMed.